Table 3.
Efficacy Outcomes in Two Groups According to RECIST v1.1 in PSM Cohort
| Variables | Evaluation | Len+PD-1 Group (n=81) |
HAIC+Len+PD-1 Group (n=81) |
P value |
|---|---|---|---|---|
| 3-Month Evaluation | CR | 0 (0) | 4 (4.9) | 0.005 |
| PR | 21 (25.9) | 37 (45.7) | ||
| SD | 36 (44.4) | 26 (32.1) | ||
| PD | 24 (29.7) | 14 (17.3) | ||
| 6-Month Evaluation | CR | 0 (0) | 5 (6.2) | 0.001 |
| PR | 17 (20.9) | 31 (38.3) | ||
| SD | 18 (22.2) | 6 (7.4) | ||
| PD | 46 (56.8) | 39 (48.1) |
Abbreviations: CR, complete response; Len, Lenvatinib; PD-1, programmed cell death protein-1; PD, progressive disease; PR, partial response; SD, stable disease.